Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Neuropharmacology. 2015 Mar 4;95:121–129. doi: 10.1016/j.neuropharm.2015.02.023

Fig. 4.

Fig. 4

Effect of VU0364770 and LSP1-2111 on the development and severity of dyskinesia and l-DOPA-induced rotations. VU0364770, 100 mg/kg had no effect on the development (AIMs development over chronic treatment period; A) or severity (AIMs during only session 6 of chronic treatment; B) of l-DOPA induced dyskinesia (n = 6/group). VU0364770, 100 mg/kg did not affect the rotational response induced by l-DOPA 6 mg/kg (C). LSP1-2111, 15 mg/kg had no effect on the development (AIMs development over chronic treatment period; D) or severity (AIMs during only session 6 of chronic treatment; E) of l-DOPA induced dyskinesia (n = 11/group). LSP1-2111, 15 mg/kg did not affect the rotational response induced by l-DOPA 6 mg/kg (F).